These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36566274)

  • 1. A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.
    Martin A; Mick GJ; Choat HM; Lunsford AA; Tse HM; McGwin GG; McCormick KL
    Nat Commun; 2022 Dec; 13(1):7928. PubMed ID: 36566274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology.
    Choat HM; Martin A; Mick GJ; Heath KE; Tse HM; McGwin G; McCormick KL
    Contemp Clin Trials; 2019 Jul; 82():93-100. PubMed ID: 31229619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
    Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
    Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes mellitus decreases the expression of calcitonin-gene related peptide, gamma-amino butyric acid and glutamic acid decarboxylase in human pancreatic islet cells.
    Al-Salam S; Hameed R; Parvez HS; Adeghate E
    Neuro Endocrinol Lett; 2009; 30(4):506-10. PubMed ID: 20010500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
    Elding Larsson H; Lundgren M; Jonsdottir B; Cuthbertson D; Krischer J;
    Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
    Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
    Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.
    Ludvigsson J; Sumnik Z; Pelikanova T; Nattero Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Katsarou A; Hanas R; Hernandez C; Clemente León M; Gómez-Gila A; Lind M; Lozano MF; Sas T; Samuelsson U; Pruhova S; Dietrich F; Puente Marin S; Nordlund A; Hannelius U; Casas R
    Diabetes Care; 2021 Jul; 44(7):1604-1612. PubMed ID: 34021020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional considerations of GABA in islets of Langerhans. Beta-cells and nerves.
    Sorenson RL; Garry DG; Brelje TC
    Diabetes; 1991 Nov; 40(11):1365-74. PubMed ID: 1936599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
    Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
    Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.
    Boettler T; Pagni PP; Jaffe R; Cheng Y; Zerhouni P; von Herrath M
    J Autoimmun; 2013 Aug; 44():40-8. PubMed ID: 23770292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
    Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
    Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes.
    Ludvigsson J; Routray I; Vigård T; Hanås R; Rathsman B; Carlsson A; Särnblad S; Albin AK; Arvidsson CG; Samuelsson U; Casas R
    Diabetes Metab Res Rev; 2021 Oct; 37(7):e3440. PubMed ID: 33486892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of gamma-aminobutyric acid on hormone release by the mouse and rat endocrine pancreas.
    Gilon P; Bertrand G; Loubatières-Mariani MM; Remacle C; Henquin JC
    Endocrinology; 1991 Nov; 129(5):2521-9. PubMed ID: 1682137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted ß-cells in diabetic NOD mice.
    Tian J; Dang H; Kaufman DL
    PLoS One; 2011; 6(9):e25337. PubMed ID: 21966502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
    N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
    Nowak C; Lind M; Sumnik Z; Pelikanova T; Nattero-Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Hanas R; Hernandez C; Clemente-León M; Gómez-Gila A; Ferrer Lozano M; Sas T; Pruhova S; Dietrich F; Puente-Marin S; Hannelius U; Casas R; Ludvigsson J
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2644-2651. PubMed ID: 35665810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
    Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
    Front Immunol; 2020; 11():564921. PubMed ID: 33162978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients.
    Zanone MM; Catalfamo E; Pietropaolo SL; Rabbone I; Sacchetti C; Cerutti F; Trucco M; Cavallo-Perin P
    Metabolism; 2003 Jan; 52(1):25-9. PubMed ID: 12524658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of GABA in islet function.
    Hagan DW; Ferreira SM; Santos GJ; Phelps EA
    Front Endocrinol (Lausanne); 2022; 13():972115. PubMed ID: 36246925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes.
    Hill H; Elksnis A; Lundkvist P; Ubhayasekera K; Bergquist J; Birnir B; Carlsson PO; Espes D
    Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.